Form 4: Regulus Therapeutics CFO Acquires 562,500 Stock Options

Regulus Therapeutics' Chief Financial Officer, Crispina Calsada, has been granted 562,500 stock options, which vest over a 48-month period.

Summary

• Crispina Calsada, the Chief Financial Officer of Regulus Therapeutics, has been granted 562,500 stock options.
• These options have an exercise price of $1 per share.
• The options began vesting on January 1, 2025, and will vest monthly over a 48-month period, contingent on Ms. Calsada's continued employment with the company.
• The options expire on January 29, 2035.

Sentiment

Score: 7

Explanation: The document reflects a standard executive compensation practice, which is generally viewed positively as it aligns management's interests with shareholders. There are no negative implications.

Positives

• The grant of stock options aligns the CFO's interests with those of the shareholders.
• The vesting schedule encourages long-term commitment from the CFO.

Risks

• The value of the options is dependent on the future performance of Regulus Therapeutics' stock price.
• If Ms. Calsada leaves the company before the options fully vest, she may forfeit some or all of the options.

Future Outlook

The stock options will vest over the next 48 months, subject to the CFO's continued employment.

Industry Context

Stock option grants are a common form of compensation for executives in the biotechnology industry, aligning their interests with the long-term success of the company.

Comparison to Industry Standards

• Stock option grants are a standard practice for executive compensation in the biotech industry.
• The vesting schedule of 48 months is typical for such grants, encouraging long-term commitment.
• The exercise price of $1 is common for options granted to executives, often set at or near the current market price at the time of grant.

Stakeholder Impact

• Shareholders may view the stock option grant positively as it incentivizes the CFO to increase the company's value.
• Employees may see this as a positive sign of the company's commitment to its leadership.

Key Dates

Keywords

stock options, Regulus Therapeutics, CFO, Crispina Calsada, equity compensation, vesting